Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22115304 | 0.84 | GABRG2 (0.52) | PLAUACLY | |
| SCHEMBL30712417 | 0.84 | GABRG2 (0.52) | PLAUACLY | |
| SCHEMBL233380 | 0.84 | VCAM1 (0.44) | KIF11NISCHHSD11B1TDO2MAOA | |
| SCHEMBL31195830 | 0.84 | VCAM1 (0.44) | KIF11NISCHHSD11B1TDO2MAOA | |
| SCHEMBL7228832 | 0.79 | KIF11 (0.49) | KIF11MMP3HSD11B1PLAUACLY | |
| SCHEMBL31463157 | 0.78 | MMP3 (0.47) | KIF11MMP3CYP11B2HSD11B1PLAU | |
| SCHEMBL24133693 | 0.78 | S1PR3 (0.36) | KIF11TDO2MAOAMAOB | |
| SCHEMBL20898226 | 0.77 | TDP2 (0.47) | NISCHTDP2ERCC1ERCC4 | |
| SCHEMBL15234719 | 0.77 | KIF11 (0.54) | KIF11MMP3CYP11B2HSD11B1CYP11B1 | |
| SCHEMBL15234505 | 0.77 | KIF11 (0.54) | KIF11MMP3CYP11B2CYP11B1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670507-B1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2023152346-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-08-17 | — | — | WO | disclosed |
| EP-3670507-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3670507-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-1735275-B1 | ARYL SULFONES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754890-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | AMGEN INC. | 2008-10-30 | — | — | US | disclosed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402704-B2 | Arylsulfones and uses related thereto | AMGEN INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1735275-A2 | ARYL SULFONES AND USES RELATED THERETO | Amgen Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005110980-A2 | ARYL SULFONES AND USES RELATED THERETO | AMGEN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269283-A1 | ARYLSULFONES AND USES RELATED THERETO | ARSA, SULT2A1, UGT2B7 | KIF11 4355/4885MMP3 1511/4885NISCH 336/4885 |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | HSD17B1, HSD3B1, HSD11B1 | KIF11 4098/4885MMP3 898/4885NISCH 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.